Lexaria Bioscience (NASDAQ:LEXX) just reported results for the third quarter of 2024.
- Lexaria Bioscience reported earnings per share of -13 cents. This was below the analyst estimate for EPS of -10 cents.
- The company reported revenue of $84,000.
- This was 44% worse than the analyst estimate for revenue of $150,000.